Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Acquisition By Opko, Prolor Poised To Become U.S. Firm’s Biologics Subsidiary

This article was originally published in The Pink Sheet Daily

Executive Summary

Opko’s third investment in the Israeli biopharmaceutical sector is a $480 million all-stock deal in which it will acquire Prolor Biotech, which specializes in developing longer-acting formulations of approved protein products. Its lead candidate is human growth hormone hGH-CTP, in development for growth hormone deficiency in adults and children.



Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts